The fund owned 2,482 shares of the pharmaceutical company’s stock after selling 785 shares during the period. SWS Partners’ holdings in Vertex Pharmaceuticals were worth $1,105,000 as of its most recent SEC filing. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year. Vertex Pharmaceuticals Company Profile(Free Report)Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.